Sio Gene Therapies Inc
SIOX
|
$0.478
-20.5%
40K
|
Health Technology
(0.0% 1d) (0.0% 1m) (14.9% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (84.8% volume)
Earnings Calendar: 2022-11-10
Market Cap: $ 35,360,144
http://www.siogtx.com
Sec Filling | Patents | 38 employees
(United Kingdom) Sio Gene Therapies Inc. is a clinical-stage biopharmaceutical company, which engages in the acquisition, development, and commercialization of gene therapies for neurological diseases. Its product pipeline focus on Parkinson's Disease, GM1 gangliosidosis, and GM2 gangliosidosis such as Tay-Sachs disease and Sandhoff disease. Axovant operates through seven wholly owned subsidiaries and also has business operations in Basel, Switzerland and New York, NY. The company was founded on October 31, 2014 and is headquartered in New York, NY.
acquisitions gene therapies parkinson neurological
add to watch list Paper trade email alert is off
Press-releases
Sio Gene Therapies, Inc. to File for Dissolution and Declare an Initial Liquidating Distribution of $0.435 Per Share
Published: 2024-02-02 (Crawled : 12:00) - globenewswire.com
SIOX | $0.478 -20.5% 40K
|
Health Technology
| Email alert
Add to watchlist
distribution
Delisting of Securities of Core Scientific, Inc.; The Very Good Food Company Inc.; HyreCar Inc.; Reeds, Inc.; Sorrento Therapeutics, Inc.; CYREN Ltd.; Lucira Health, Inc.; Qutoutiao Inc.; and Sio Gene Therapies Inc. from The Nasdaq Stock Market
Published: 2023-04-10 (Crawled : 21:00) - globenewswire.com
CYRNQ | $0.0001 0% 600
|
n/a
|
| O: -16.8%
H: 75.48%
C: 55.29%
HYREQ | $0.0002 4300.0% 120K
|
n/a
|
| O: -19.89%
H: 34.04%
C: 34.04%
SIOX | $0.478 -20.5% 40K
|
Health Technology
|
| O: 0.0%
H: 0.43%
C: 0.0%
SRNE | $0.015 -8.85% 140K
|
Health Technology
|
| O: 0.25%
H: 2.1%
C: -3.38%
NDAQ | $61.095 -0.17% -0.17% 2.3M
|
Finance
|
| O: 0.0%
H: 0.59%
C: -0.06%
food market
Sio Gene Therapies Announces Fiscal Third Quarter 2022 Financial Results
Published: 2023-02-14 (Crawled : 18:00) - biospace.com/
SIOX | $0.478 -20.5% 40K
|
Health Technology
|
| O: 0.0%
H: 2.39%
C: 0.39%
financial results
Sio Gene Therapies Inc. Announces Board Approval of Plan of Complete Liquidation and Dissolution
Published: 2022-12-14 (Crawled : 22:00) - globenewswire.com
SIOX | $0.478 -20.5% 40K
|
Health Technology
|
| O: 8.85%
H: 4.85%
C: 4.85%
approval
Sio Gene Therapies Announces Fiscal First Quarter 2022 Financial Results
Published: 2022-08-11 (Crawled : 16:00) - biospace.com/
SIOX | $0.478 -20.5% 40K
|
Health Technology
|
| O: 1.39%
H: 8.29%
C: -2.86%
results
Sio Gene Therapies Announces Fiscal Year 2021 Year-End Financial Results
Published: 2022-06-14 (Crawled : 12:00) - biospace.com/
ROIV | $10.935 3.16% 3.06% 5M
|
Manufacturing
|
| O: 1.42%
H: 8.68%
C: 4.62%
SIOX | $0.478 -20.5% 40K
|
Health Technology
|
| O: 1.35%
H: 2.78%
C: -1.39%
year results therapy
Sio Gene Therapies Announces Prioritization of Lead Gene Therapy Programs in GM1 and GM2 Gangliosidosis, Extension of Cash Runway, and CEO Transition
Published: 2022-01-31 (Crawled : 23:00) - biospace.com/
SIOX | $0.478 -20.5% 40K
|
Health Technology
|
| O: -1.87%
H: 14.29%
C: 11.43%
gene therapy program ceo gene therapies therapy
Sio Gene Therapies Announces Corporate Updates and Fiscal Second Quarter 2021 Financial Results
Published: 2021-11-12 (Crawled : 23:00) - biospace.com/
ROIV | $10.935 3.16% 3.06% 5M
|
Manufacturing
|
| O: -0.38%
H: 9.11%
C: 7.83%
SIOX | $0.478 -20.5% 40K
|
Health Technology
|
| O: -4.48%
H: 4.17%
C: 3.65%
financial results gene therapies results therapy gene therapy
Sio Gene Therapies Announces Successful Manufacture of Three GMP Batches of AXO-Lenti-PD Gene Therapy for Parkinson’s Disease
Published: 2021-11-11 (Crawled : 14:00) - biospace.com/
SIOX | $0.478 -20.5% 40K
|
Health Technology
|
| O: 2.07%
H: 2.54%
C: 2.03%
disease gene therapies gene therapy therapy parkinson
Sio Gene Therapies Announces Granting of FDA Fast Track Designation for Investigational AXO-AAV-GM2 Gene Therapy in Patients with GM2 Gangliosidosis
Published: 2021-11-01 (Crawled : 19:00) - biospace.com/
SIOX | $0.478 -20.5% 40K
|
Health Technology
|
| O: 0.0%
H: 6.28%
C: 6.28%
fda fda fast track gene therapies fast track gene therapy therapy fast track designation designation
Last 15 days Sec forms
| File Id | Form | Published Date | Transaction Date | Direction | Code | Amount Transacted | Owned Amount |
Your Today's Watch List
Sign in to create a watchlistGainers vs Losers
| 78% | 22% |
Top 10 Gainers
MTTR | News 4 | $4.6 164.37% 62.17% 28M
|
AGBA | $2.94 135.2% 57.48% 66M
|
Finance
EDBL | News | $6.46 71.81% 41.8% 2M
|
MTC | $2.25 44.23% 30.67% 6M
|
Technology Services
OPRT | News | $3.175 41.11% 29.13% 12M
|
Finance
SHIM | $3.05 35.56% 26.23% 1.1M
|
HKIT | $1.345 31.86% 24.16% 390K
|
Technology Services
ABVC | $1.36 30.77% 23.53% 7.4M
|
Wholesale Trade
OST | $0.512 28.0% 21.88% 290K
|
POET | $1.59 27.2% 21.38% 4.2M
|
Manufacturing
Last 48 Hours Insiders Buying
MEGI | $11.975 1.87% 0.04% 140K
|
|
00:30
CTRN P 29000 | $22.25 0.14% 0.13% 100K
|
Retail Trade
|
22:00
CONN | $3.71 1.37% 1.35% 72K
|
Retail Trade
|
21:30
TGEN P 6000 | $0.6897 39.71% 2.3K
|
Utilities
|
18:30
CMTV P 700 | $15.74 17.43% 12K
|
Finance and Insurance
|
18:30
FNB | $13.63 2.17% 0.0% 2.5M
|
Finance
|
17:30
RMCF | $3.57 0.28% 2.8K
|
Consumer Non-Durables
|
20:10